Skip to main content

Advertisement

Table 2 Response to EGFR-TKIs in 453 NSCLC patients with different EGFR genotypes

From: Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

Variate Exon 19 deletion (n = 270) Exon 21 L858R mutation (n = 183) P valuea
Best response (cases)   0.074
 CR 4 2  
 PR 145 78  
 SD 105 84  
 PD 16 19  
MDT (months)
 CR/PR 13.0 14.6 0.874
 SD 13.7 11.9 0.193
ORR (%)
 Total 55.2 43.7 0.017
 Line 1 60.0 49.5 0.108
 Line ≥ 2 49.6 32.4 0.018
 Gefitinib 59.2 43.2 0.005
 Erlotinib 55.8 39.1 0.184
 Icotinib 33.3 58.8 0.089
DCR (%)
 Total 94.1 89.6 0.081
 Line 1 96.2 92.4 0.208
 Line ≥2 91.7 84.5 0.113
  1. CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, ORR = CR + PR, DCR disease control rate, DCR = CR + PR + SD, MDT median duration of treatment, ECOG Eastern Cooperative Oncology Group, PS performance status, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor
  2. aAnalyzed by using χ2 test